Breakthrough in understanding lung cancer vulnerabilities points the way to new targeted therapy

October 1, 2012

More effective treatments for one of the deadliest forms of cancer are one step closer thanks to groundbreaking research from an international collaborative study.

Scientists from the Universities of Sheffield and Cologne have identified the dependencies of multiple Small Cell Lung Cancer (SCLC) types – paving the way for clinical trials of new targeted treatments which could revolutionise the current approach.

Around 40,000 people are diagnosed annually with lung cancer in the UK, and SCLC accounts for nearly one in five of all these cases.

Unfortunately, the prognosis for SCLC patients is very bleak – two thirds of people are diagnosed in the late stages of the disease when the five year survival rate with current treatments is less than five per cent.

But now researchers have discovered that survival of SCLC cells grown from human tumours relies upon a protein called Aurora kinase. This finding, published today in the journal Proceeding of the National Academy of Sciences (PNAS), suggests that 'targeted' therapeutic strategies should focus on testing Aurora kinase inhibitors, several of which have already been developed by pharmaceutical companies.

The team also went on to show that Aurora kinase inhibitors are most effective at killing SCLC cells when the cells have high levels of the MYC . This predicts that these drugs might be most beneficial for SCLC patients with a MYC , which is found in up to seven per cent of people diagnosed with SCLC.

Dr Patrick Eyers, from the University of Sheffield's Institute for , said: "A major goal of modern cancer research is to discover drugs that vulnerabilities in specific sub-populations. Current chemotherapy for SCLC kills and non-cancerous cells indiscriminately and results in severe side effects.

"However, revolutionary clinical trials have recently validated 'molecularly targeted' kinase inhibitors for treating cancers such as melanoma, leukaemia and non-small cell lung cancer.

"We have been studying Aurora kinase inhibitors for several years, and the remarkable vulnerability of some SCLC-derived cells to such drugs can hopefully be rapidly confirmed by careful stratification of SCLC patients and their enrolment in new clinical trials."

Explore further: Chemotherapy effective for patients with resected SCLC or large-cell neuroendocrine carcinoma

Related Stories

Chemotherapy effective for patients with resected SCLC or large-cell neuroendocrine carcinoma

June 15, 2012
Research presented in the July 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concluded that patients with limited large cell neuroendocrine tumors or with ...

A new approach to cancer treatment published

October 10, 2011
(Medical Xpress) -- Scientists have discovered a mechanism that causes an aggressive type of lung cancer to re-grow following chemotherapy, offering hope for new therapies.

Recommended for you

One in five young colon cancer patients have genetic link

December 13, 2017
As doctors grapple with increasing rates of colorectal cancers in young people, new research from the University of Michigan may offer some insight into how the disease developed and how to prevent further cancers. Researchers ...

New strategy for unleashing cancer-fighting power of p53 gene

December 13, 2017
Tumor protein p53 is one of the most critical determinants of the fate of cancer cells, as it can determine whether a cell lives or dies in response to stress. In a new study published today in the journal Nature Communications, ...

Researchers develop test that can diagnose two cancer types

December 12, 2017
A blood test using infrared spectroscopy can be used to diagnose two types of cancer, lymphoma and melanoma, according to a study led by Georgia State University.

Cancer-causing mutation suppresses immune system around tumours

December 12, 2017
Mutations in 'Ras' genes, which drive 25% of human cancers by causing tumour cells to grow, multiply and spread, can also protect cancer cells from the immune system, finds a new study from the Francis Crick Institute and ...

Atoh1, a potential Achilles' heel of Sonic Hedgehog medulloblastoma

December 12, 2017
Medulloblastoma is the most common type of solid brain tumor in children. Current treatments offer limited success and may leave patients with severe neurological side effects, including psychiatric disorders, growth retardation ...

MRI scans predict patients' ability to fight the spread of cancer

December 12, 2017
A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.